Bracco Features its Mission of 'No Compromise in MRI' at RSNA 2022

Bracco Diagnostics Inc. (Monroe Township, N.J., USA), the US subsidiary of Bracco Imaging S.p.A., is featuring the recently FDA-approved Gadopiclenol Injection, a novel, highly stable macrocyclic gadolinium-based contrast agent (GBCA), commercialized as VUEWAY (gadopiclenol) injection by Bracco, among a robust line of imaging products, devices, and support solutions, at RSNA 2022.

Bracco is offering several engagement opportunities at RSNA 2022, including Meet and Connect with Peers during a media briefing that will profile 'No Compromise in Magnetic Resonance Imaging (MRI),' to summarize the company's comprehensive support and education, and spotlight the new category that VUEWAY injection creates for imaging agents. Bracco is also offering ‘Celebrate our Leaders on the Horizon’, an exclusive radiology residency program in which continuing education scholarships are awarded to five radiology residents whose submitted research papers are selected for publication in a special supplement to Applied Radiology. Visitors to the Bracco booth can experience its innovation throughout all diagnostic imaging modalities, including its Smartinject contrast delivery platforms, innovative informatics solutions, and best-in-class service offerings.

“We can think of no better venue to further educate and connect with our peers and industry partners than at RSNA, the world's largest medical imaging forum,” said Cosimo De Pinto, Senior Vice President, Sales and Marketing at Bracco Diagnostics Inc. “We've taken this year's congress theme of 'empowering patients and partners in our care' to heart, working hard to ensure our customers can look deeper and remain confident in the care they provide their patients. We are united in driving forward the next generation of diagnostic solutions as we unveil VUEWAY injection and work to fulfill our own mission of 'No Compromise in MRI'.”

Related Links:
Bracco Diagnostics Inc.